← FDA DRUG APPROVALS

FDA NDA · NDA021267

VFEND

voriconazole

Sponsor: PF PRISM CV

APPLICATION
NDA021267
TYPE
NDA
ORIGINAL APPROVAL
2002-05-24
LATEST ACTION
2026-02-19
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

VFEND · ReferencePrescription
VORICONAZOLE 200MG/VIAL · POWDER · INTRAVENOUS

Approval history

2026-02-19Labeling · Supplement 70 · standardLetterAP
2026-01-28Labeling · Supplement 69 · standardLabelAP
2025-03-12Labeling · Supplement 67 · standardLetterAP
2022-10-18Labeling · Supplement 63 · standardLetterAP
2022-08-16Labeling · Supplement 64 · standardLetterAP
2022-01-28Labeling · Supplement 62 · standardLetterAP
2021-10-13Labeling · Supplement 61 · standardLetterAP
2021-04-15Labeling · Supplement 60 · standardLabelAP
2021-01-25Labeling · Supplement 59 · standardLabelAP
2021-01-14Labeling · Supplement 57 · standardLetterAP
2020-09-04Labeling · Supplement 58 · standardLabelAP
2019-04-30Labeling · Supplement 55 · standardLabelAP
2019-01-29Efficacy · Supplement 50 · priorityLabelAP
2017-07-28Labeling · Supplement 54 · standardLabelAP
2017-06-15Labeling · Supplement 53 · standardLetterAP
2016-01-15Manufacturing (CMC) · Supplement 48 · standardAP
2015-02-03Labeling · Supplement 47 · standardLetterAP
2014-06-24Manufacturing (CMC) · Supplement 46 · standardAP
2014-06-09Manufacturing (CMC) · Supplement 45 · standardAP
2014-04-07Labeling · Supplement 44 · standardLetterAP
2013-07-25Manufacturing (CMC) · Supplement 42 · standardAP
2011-11-16Labeling · Supplement 40 · standardLabelAP
2011-06-01Labeling · Supplement 37 · unknownLabelAP
2010-12-15Labeling · Supplement 34 · unknownLetterAP
2010-11-21Labeling · Supplement 36 · unknownLetterAP
2010-06-17Labeling · Supplement 32 · unknownLetterAP
2010-06-17Labeling · Supplement 29 · standardLetterAP
2010-06-17Labeling · Supplement 33 · unknownLetterAP
2010-06-17Labeling · Supplement 25 · standardLetterAP
2008-05-30Labeling · Supplement 26 · standardLetterAP
2008-03-10Labeling · Supplement 24 · standardLabelAP
2008-02-05Labeling · Supplement 16 · standardLabelAP
2006-12-01Labeling · Supplement 21 · standardLetterAP
2006-05-19Labeling · Supplement 19 · standardLabelAP
2006-03-10Labeling · Supplement 15 · standardLabelAP
2005-12-18Labeling · Supplement 12 · standardLetterAP
2005-07-07Labeling · Supplement 11 · standardLabelAP
2005-03-24Labeling · Supplement 10 · standardLabelAP
2004-12-21Efficacy · Supplement 9 · standardLabelAP
2004-04-21Labeling · Supplement 5 · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →